Abstract
Antibody-mediated rejection of a kidney allograft can be caused by non-human leukocyte antigen (HLA) antibodies such as Angiotensin Type 1 Receptor (AT1R) antibodies. AT1R antibodies are associated with an increased risk of early rejection and reduced long-term allograft survival. Although infrequent, a high index of suspicion for AT1R antibody-mediated rejection is warranted when there is histologic evidence of antibody-mediated injury in the allograft but no identified donor-specific HLA antibody. Treatment options for AT1R antibody-mediated rejection include the use of angiotensin receptor blockade in addition to other antibody-directed therapies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Philogene M, Johnson T, Vaught A, et al. Antibodies against angiotensin II type 1 and endothelin a receptors: relevance and pathogenicity. Hum Immunol. 2019;80:561–7. https://doi.org/10.1016/j.humimm.2019.04.012.
Dragun D, Muller D, Brasen J, et al. Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med. 2005;352:558–69.
Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 2013;13:2567–76. https://doi.org/10.1111/ajt.12397.
Lefaucher C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019;96:189–201. https://doi.org/10.1016/j.kint.2019.01.030.
Carrol R, Riceman M, Hope C, et al. Angiotensin II type-1 receptor antibody (AT1Rab) associated with humoral rejection and the effect of peri operative plasma exchange and candesartan. Hum Immunol. 2016;77:1154–8. https://doi.org/10.1016/j.humimm.2016.08.009.
Karpel H, Ali N, Lawson N, et al. Successful A2 to B deceased donor kidney transplant after desensitization for high-strength non-HLA antibody made possible by utilizing a hepatitis C positive donor. Case Reports in Transplantation. 2020; https://doi.org/10.1155/2020/3591274.
Philogene M, Zhou S, Lonze B, et al. Pre-transplant screening for non-HLA antibodies: who should be tested? Hum Immunol. 2018;79:195–202. https://doi.org/10.1016/j.humimm.2018.02.001.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sarrell, B.A., Concepcion, B.P. (2022). Angiotensin Type 1 Receptor Antibody-Mediated Rejection in a Kidney Transplant Recipient. In: Aziz, F., Parajuli, S. (eds) Complications in Kidney Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-031-13569-9_37
Download citation
DOI: https://doi.org/10.1007/978-3-031-13569-9_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-13568-2
Online ISBN: 978-3-031-13569-9
eBook Packages: MedicineMedicine (R0)